News | April 06, 2022
AGC to invest $100 million for expanding synthetic pharmaceutical production in Spain
The new facility is scheduled to start operation in the first half of 2024
The new facility is scheduled to start operation in the first half of 2024
Support for bioprocess, cell and gene therapy, and industry 4.0 initiatives
Announces pilot project for rapid, remote diagnosis of tuberculosis
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The two-day event will showcase achievements and address issues pertaining to the industry
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Subscribe To Our Newsletter & Stay Updated
